Furthermore, loss-of-function mutations in KDM6A render bladder cancer cells susceptible to EZH2 inhibitors, which drive cell differentiation and death (Ramakrishnan et al., 2019). The gene discussed is KDM6A; the disease is urinary bladder carcinoma.